Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Varicella zoster is also known as Human alphaherpesvirus 3 and causes chicken pox and herpes zoster in humans. The infection caused by this virus can be prevented by the use of vaccinations that are specially formulated to provide immunity against the virus. There are mainly two types of vaccinations available to provide immunity against varicella zoster such as monovalent varicella vaccine and combination varicella vaccine.
Market Analysis and Insights: Global Varicella Live Vaccine Market
The global Varicella Live Vaccine market is valued at US$ 2361 million in 2019. The market size will reach US$ 2957.2 million by the end of 2026, growing at a CAGR of 3.2% during 2021-2026.
Global Varicella Live Vaccine Scope and Market Size
Varicella Live Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Varicella Live Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Monovalent Varicella Vaccine
Combination Varicella Vaccine
Segment by Application
Chickenpox Immunization
Herpes Zoster Immunization
Measles, Mumps, Rubella and Varicella (MMRV) Immunization
By Company
Bio-Med Pvt. Limited
Changchun BCHT Biotechnology
Emcure Pharmaceuticals
GlaxoSmithKline
GC Pharma
Merck & Co. Inc.
Mitsubishi Tanabe Pharma
Novo Medi Sciences
Sanofi
Takeda Pharmaceutical Company Limited.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
Market Analysis and Insights: Global Varicella Live Vaccine Market
The global Varicella Live Vaccine market is valued at US$ 2361 million in 2019. The market size will reach US$ 2957.2 million by the end of 2026, growing at a CAGR of 3.2% during 2021-2026.
Global Varicella Live Vaccine Scope and Market Size
Varicella Live Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Varicella Live Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Monovalent Varicella Vaccine
Combination Varicella Vaccine
Segment by Application
Chickenpox Immunization
Herpes Zoster Immunization
Measles, Mumps, Rubella and Varicella (MMRV) Immunization
By Company
Bio-Med Pvt. Limited
Changchun BCHT Biotechnology
Emcure Pharmaceuticals
GlaxoSmithKline
GC Pharma
Merck & Co. Inc.
Mitsubishi Tanabe Pharma
Novo Medi Sciences
Sanofi
Takeda Pharmaceutical Company Limited.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
